High-yield and high-throughput afucosylated mAb expression benefits therapeutic antibody efficacy

3 October 2022

*Sponsored content

The latest in a series of Industry Leader pieces from biological reagent supplier and service provider Sino Biological.

An absence of fucose residues on the antibody Immunoglobulin γ (IgG) constant (Fc) region N-glycan moiety has been demonstrated to increase the binding affinity to IgG-Fc-receptor (FcγR) IIIa. It results in increased antibody-dependent cellular cytotoxicity (ADCC) since this receptor is found on immune effector cells like natural killer cells. Sino Biological establishes a proprietary “FucoFree” eukaryotic cell culture system for the custom expression of afucosylated mAbs. We provide high-yield and high-throughput antibody expression with >95% purity and low endotoxin level (<1 EU/mg).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK